Summary
The biliary excretion of ranitidine and famotidine has been studied using percutaneous biliary drainage in patients with complete extrahepatic biliary obstruction due to pancreatic carcinoma.
Following 50 mg ranitidine i. v. 0.7 to 2.6% of the dose was recovered in bile collected over 24 h. At steady state (300 mg ranitidine/d po) a similar amount (0.3 to 1.0% of daily dose) was excreted by this route (n = 3). Following single i.v. (20 mg) and oral (40 mg) doses of famotidine (n = 2), even lower percentages (0.1% and 0.4%, respectively) were recovered in the 24 h bile.
This negligible biliary excretion cannot account for the so-called second peak phenomenon observed in some individuals following a single dose of an H2-receptor antagonist.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Somogyi A, Gugler R (1983) Clinical pharmacokinetics of cime- tidine. Clin Pharmacokinet 8:463–495
Roberts CJC (1984) Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet 9:211–221
Krishna DR, Klotz U (1988) Newer H2-receptor antagonists — clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15:205–215
Kroemer H, Klotz U (1987) Pharmacokinetics of famotidine in man. Intern J Clin Pharmacol Ther Toxico1 25:458–463
van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, de Schepper PJ (1982) Rmlitidine: single dose pharmacokinetics and absolute bioavailaility in man. Br J Clin Pharmaco1 14:195–200
Boutagy J, More DG, Munro IA, Shenfield GM (1984) Simulta- neous analysis of cimetidine and ranitidine in human plasma by HPLC. J Liquid Chromatogr 7:1651–1664
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klotz, U., Walker, S. Biliary excretion of H2-receptor antagonists. Eur J Clin Pharmacol 39, 91–92 (1990). https://doi.org/10.1007/BF02657067
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02657067